Market Intelligence, Clinical Progress, and High-Purity Reagents for Metabolic and Obesity Therapeutic Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for PPYR1/NPY4R drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PPYR1/NPY4R Recombinant Accessory Proteins / Ligands (Pancreatic Polypeptide) High purity (>95%), Endotoxin controlled. Sequence Verified. Suitable for binding assays. |
View PPYR1 Products |
| Gene Delivery | PPYR1/NPY4R Promise-ORF / Lentivirus Full-length human PPYR1/NPY4R ORF for stable cell line generation. Essential for preserving GPCR multi-pass transmembrane conformation. |
View PPYR1 Products |
| Benchmark Ab | Anti-PPYR1/NPY4R Recombinant Control Antibody Recombinant sequence-verified positive control for flow cytometry and binding validation. |
View PPYR1 Products |
| Validator | PPYR1/NPY4R siRNA Set Target-specific knockdown verification in functional cell-based assays. |
View PPYR1 Products |
| Related Target A | GLP1R Synergistic metabolic pathway target. Co-agonism of GLP1R and PPYR1 represents a key strategy in next-generation weight-loss therapeutics. |
View GLP1R Products |
| Related Target B | NPY2R Y receptor subfamily member. Crucial counter-screening target to verify subtype selectivity and avoid off-target side effects. |
View NPY2R Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| GPCR Native Conformation Preservation | Lentivirus-mediated stable cell line construction ensures native 7-transmembrane folding for functional calcium flux and cAMP assays. |
| Subfamily Off-Target Cross-Screening | Homolog panel reagents (NPY1R, NPY2R, NPY5R) strictly verified by mass spectrometry and sequence analysis for counter-screening. |
| Lack of Controls | Recombinant benchmark antibodies and positive control ligands included in the portfolio. |
| False Positives in Screening | Sequence-verified siRNA pool included for target knockdown validation. |
Live PPYR1/NPY4R R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for PPYR1/NPY4R therapeutics is intensifying, with major players shifting focus from traditional mono-agonist peptides to multi-receptor co-agonists (e.g., dual GLP-1R/NPY4R or triple GLP-1R/GIPR/NPY4R agonists). As first-generation obesity therapies reach the clinic, the next wave of R&D is targeting sustained appetite suppression and improved tolerability profiles by leveraging the synergistic pathway of Pancreatic Polypeptide (PP) receptor activation.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Peptide Co-agonists | Novo Nordisk, Eli Lilly | Obesity, Type 2 Diabetes | Functional GPCR activation assays (Need Lentivirus for high-expression stable cell lines) |
| Monoclonal Antibodies | Biotech Developers | Prader-Willi Syndrome, Eating Disorders | Conformational epitope binding (Need cell-based Flow Cytometry validation) |
| Small Molecule Agonists | Global Pharma | Metabolic Syndrome | Selectivity profiling (Need NPY receptor subfamily counter-screening panels) |